DyslipidemiaPhase 3FOURIERNCT01764633

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

A Phase 3 study testing Evolocumab in people with Dyslipidemia, run by Amgen at 1,284 sites in 49 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular… Read more about this study

Who is it for?: Ages 40 to 85 years
Conditions the study is for: Dyslipidemia
What is being tested?: Evolocumab
Type of treatment: Injection or infusion
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 27,564 participants
Where: 1,284 sitesin 49 countries
Study dates: 8 Feb 2013to 11 Nov 2016
Phase: Phase 3
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 to 85 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Male or female ≥ 40 to ≤ 85 years of age
History of clinically evident cardiovascular disease at high risk for a recurrent event
Fasting low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (> 2.6 mmol/L)
Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Who cannot join

New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction < 30%
Uncontrolled hypertension
Uncontrolled or recurrent ventricular tachycardia
Untreated hyperthyroidism or hypothyroidism
Homozygous familial hypercholesterolemia
LDL or plasma apheresis

Trial locations and contacts

1,284 sites in 49 countries.

Country

City, postcode or hospital

1258 sites in 49 countries

United States300 sites

Research Site
Abington, Pennsylvania, 19001
Research Site
Addison, Illinois, 60101
Research Site
Albany, New York, 12208
Research Site
Alhambra, California, 91801
Research Site
Altoona, Pennsylvania, 16602
Research Site
Ames, Iowa, 50010
Research Site
Anchorage, Alaska, 99508
Research Site
Anderson, South Carolina, 29621
Research Site
Ann Arbor, Michigan, 48106
Research Site
Annapolis, Maryland, 21401
Research Site
Arlington, Texas, 76012
Research Site
Asheville, North Carolina, 28801
Research Site
Asheville, North Carolina, 28805
Research Site
Athens, Georgia, 30606
Research Site
Atlanta, Georgia, 30342
Research Site
Atlantis, Florida, 33462
Research Site
Auburn, Maine, 04210
Research Site
Augusta, Georgia, 30909
Research Site
Aurora, Colorado, 80012
Research Site
Austin, Texas, 78758
Research Site
Aventura, Florida, 33180
Research Site
Ayer, Massachusetts, 01432
Research Site
Baltimore, Maryland, 21201
Research Site
Baltimore, Maryland, 21204
Research Site
Baltimore, Maryland, 21236
Research Site
Baltimore, Maryland, 21237
Research Site
Bangor, Maine, 04401
Research Site
Banning, California, 92220
Research Site
Baton Rouge, Louisiana, 70808
Research Site
Bay Pines, Florida, 33744
Research Site
Belleville, Illinois, 62220
Research Site
Bend, Oregon, 97701
Research Site
Beverly Hills, California, 90211
Research Site
Biddeford, Maine, 04005
Research Site
Billerica, Massachusetts, 01821
Research Site
Billings, Montana, 59101
Research Site
Billings, Montana, 59102
Research Site
Birmingham, Alabama, 35235
Research Site
Birmingham, Alabama, 35294
Research Site
Boise, Idaho, 83704
Research Site
Boise, Idaho, 83706
Research Site
Boynton Beach, Florida, 33472
Research Site
Bradenton, Florida, 34205
Research Site
Bridgeport, Connecticut, 06610
Research Site
Buffalo, New York, 14203
Research Site
Buffalo, New York, 14215
Research Site
Burke, Virginia, 22015
Research Site
Calabash, North Carolina, 28467
Research Site
Camp Hill, Pennsylvania, 17011
Research Site
Canton, Ohio, 44710
Research Site
Cary, North Carolina, 27518
Research Site
Chambersburg, Pennsylvania, 17201
Research Site
Charleston, South Carolina, 29407
Research Site
Charleston, South Carolina, 29425
Research Site
Charlotte, North Carolina, 28204
Research Site
Charlotte, North Carolina, 28277
Research Site
Charlotte Hall, Maryland, 20622
Research Site
Chicago, Illinois, 60616
Research Site
Cincinnati, Ohio, 45219
Research Site
Cincinnati, Ohio, 45224
Research Site
Clearwater, Florida, 33756
Research Site
Cleveland, Ohio, 44195
Research Site
Coeur d'Alene, Idaho, 83814
Research Site
Colorado Springs, Colorado, 80907
Research Site
Colorado Springs, Colorado, 80909
Research Site
Columbia, Maryland, 21044
Research Site
Columbia, Maryland, 21045
Research Site
Columbia, Missouri, 65212
Research Site
Columbia, South Carolina, 29204
Research Site
Columbus, Ohio, 43201
Research Site
Columbus, Ohio, 43215
Research Site
Cortlandt Manor, New York, 10567
Research Site
Covington, Louisiana, 70433
Research Site
Cranston, Rhode Island, 02920
Research Site
Crystal River, Florida, 34429
Research Site
Cumberland, Rhode Island, 02864
Research Site
Dallas, Texas, 75216
Research Site
Danville, Virginia, 24541
Research Site
Dayton, Ohio, 45414
Research Site
Daytona Beach, Florida, 32117
Research Site
Dearborn, Michigan, 48124
Research Site
Deerfield Beach, Florida, 33442
Research Site
Delray Beach, Florida, 33484
Research Site
Denver, Colorado, 80218
Research Site
Des Moines, Iowa, 50266
Research Site
Dunwoody, Georgia, 30338
Research Site
Durham, North Carolina, 27710
Research Site
East Point, Georgia, 30344
Research Site
Eatonton, Georgia, 31024
Research Site
Edgewater, Florida, 32141
Research Site
Elizabeth, New Jersey, 07202
Research Site
Elyria, Ohio, 44035
Research Site
Encino, California, 91436
Research Site
Escondido, California, 92029
Research Site
Evansville, Indiana, 47714
Research Site
Fall River, Massachusetts, 02720
Research Site
Falls Church, Virginia, 22042
Research Site
Fargo, North Dakota, 58122
Research Site
Feasterville, Pennsylvania, 19053
Research Site
Federal Way, Washington, 98003
Research Site
Fleming Island, Florida, 32003
Research Site
Flint, Michigan, 48532
Research Site
Fort Lauderdale, Florida, 33308
Research Site
Fountain Inn, South Carolina, 29644
Research Site
Gainesville, Georgia, 30501
Research Site
Garfield Heights, Ohio, 44125
Research Site
Germantown, Tennessee, 38138
Research Site
Glendale, Arizona, 85306
Research Site
Glendale, California, 91204
Research Site
Grand Forks, North Dakota, 58201
Research Site
Grandville, Michigan, 49418
Research Site
Grapevine, Texas, 76051
Research Site
Great Falls, Montana, 59405
Research Site
Greeley, Colorado, 80631
Research Site
Green Bay, Wisconsin, 54301
Research Site
Greensboro, North Carolina, 27408
Research Site
Hammond, Louisiana, 70403
Research Site
Harbor City, California, 90710
Research Site
Haverhill, Massachusetts, 01830
Research Site
Hazel Crest, Illinois, 60429
Research Site
Hickory, North Carolina, 28601
Research Site
High Point, North Carolina, 27262
Research Site
Hollywood, Florida, 33021
Research Site
Hollywood, Maryland, 20636
Research Site
Hopewell, Virginia, 23860
Research Site
Houston, Texas, 77025
Research Site
Houston, Texas, 77030
Research Site
Houston, Texas, 77070
Research Site
Houston, Texas, 77074
Research Site
Huntington Beach, California, 92646
Research Site
Huntsville, Alabama, 35801
Research Site
Hutchinson, Kansas, 67502
Research Site
Hyannis, Massachusetts, 02601
Research Site
Indiana, Pennsylvania, 15701
Research Site
Indianapolis, Indiana, 46227
Research Site
Indianapolis, Indiana, 46237
Research Site
Indianapolis, Indiana, 46260
Research Site
Iowa City, Iowa, 52242
Research Site
Jackson, Tennessee, 38305
Research Site
Jacksonville, Florida, 32216
Research Site
Jacksonville Beach, Florida, 32250
Research Site
Jefferson City, Missouri, 65109
Research Site
Jersey Shore, Pennsylvania, 17740
Research Site
Jerseyville, Illinois, 62052
Research Site
Johnston, Rhode Island, 02919
Research Site
Kalispell, Montana, 59901
Research Site
Kansas City, Kansas, 66160
Research Site
Kansas City, Missouri, 64128
Research Site
Kerrville, Texas, 78028
Research Site
Kingston, New York, 12401
Research Site
Lafayette, Louisiana, 70508
Research Site
Laguna Hills, California, 92653
Research Site
Lakeland, Florida, 33805
Research Site
Lansing, Michigan, 48912
Research Site
Largo, Florida, 33777
Research Site
Las Vegas, Nevada, 89128
Research Site
Layton, Utah, 84041
Research Site
Lenoir, North Carolina, 28645
Research Site
Lexington, Kentucky, 40504
Research Site
Lincoln, Nebraska, 68506
Research Site
Littleton, Colorado, 80120
Research Site
Long Beach, California, 90807
Research Site
Long Beach, California, 90822
Research Site
Longmont, Colorado, 80501
Research Site
Longview, Texas, 75605
Research Site
Los Alamitos, California, 90720
Research Site
Los Angeles, California, 90033
Research Site
Los Angeles, California, 90048
Research Site
Macon, Georgia, 31201
Research Site
Madison, Wisconsin, 53713
Research Site
Marion, Ohio, 43302
Research Site
Marshfield, Wisconsin, 54449
Research Site
Melbourne, Florida, 32901
Research Site
Memphis, Tennessee, 38112
Research Site
Meridian, Idaho, 83642
Research Site
Metairie, Louisiana, 70006
Research Site
Miami, Florida, 33144
Research Site
Miami, Florida, 33155
Research Site
Miami, Florida, 33173
Research Site
Minneapolis, Minnesota, 55417
Research Site
Missoula, Montana, 59802
Research Site
Mobile, Alabama, 36608
Research Site
Moncks Corner, South Carolina, 29461
Research Site
Monroe, Louisiana, 71203
Research Site
Mooresville, North Carolina, 28117
Research Site
Mt. Pleasant, South Carolina, 29464
Research Site
Munster, Indiana, 46321
Research Site
Murray, Utah, 84107
Research Site
Muskegon, Michigan, 49444
Research Site
Nampa, Idaho, 83686
Research Site
Nashville, Tennessee, 37203
Research Site
Nashville, Tennessee, 37205
Research Site
Nashville, Tennessee, 37208
Research Site
Natchitoches, Louisiana, 71457
Research Site
New Hyde Park, New York, 11042
Research Site
New Port Richey, Florida, 34653
Research Site
New Windsor, New York, 12553
Research Site
New York, New York, 10021
Research Site
New York, New York, 10029
Research Site
New York, New York, 10033
Research Site
New York, New York, 10036
Research Site
Newark, Delaware, 19718
Research Site
Newport Beach, California, 92663
Research Site
Newton, Massachusetts, 02459
Research Site
Norristown, Pennsylvania, 19401
Research Site
North Myrtle Beach, South Carolina, 29582
Research Site
Novi, Michigan, 48374
Research Site
Oceanside, California, 92056
Research Site
Odessa, Texas, 79761
Research Site
Oklahoma City, Oklahoma, 73135
Research Site
Old Point Station, South Carolina, 29707
Research Site
Olive Branch, Mississippi, 38654
Research Site
Omaha, Nebraska, 68131
Research Site
Orangeburg, South Carolina, 29118
Research Site
Orlando, Florida, 32806
Research Site
Overland Park, Kansas, 66210
Research Site
Owensboro, Kentucky, 42303
Research Site
Oxnard, California, 93030
Research Site
Palm Harbor, Florida, 34684
Research Site
Palm Springs, California, 92262
Research Site
Pawtucket, Rhode Island, 02860
Research Site
Pembroke Pines, Florida, 33024
Research Site
Pembroke Pines, Florida, 33028
Research Site
Pensacola, Florida, 32501
Research Site
Philadelphia, Pennsylvania, 19104
Research Site
Philadelphia, Pennsylvania, 19107
Research Site
Philadelphia, Pennsylvania, 19152
Research Site
Phoenix, Arizona, 85015
Research Site
Phoenix, Arizona, 85018
Research Site
Phoenix, Arizona, 85054
Research Site
Pittsburgh, Pennsylvania, 15206
Research Site
Plano, Texas, 75023
Research Site
Plano, Texas, 75024
Research Site
Ponte Vedra, Florida, 32081
Research Site
Port Charlotte, Florida, 33952
Research Site
Portland, Maine, 04101
Research Site
Portland, Oregon, 97225
Research Site
Portland, Oregon, 97239
Research Site
Pryor, Oklahoma, 74362
Research Site
Quincy, Illinois, 62301
Research Site
Quincy, Massachusetts, 02169
Research Site
Raleigh, North Carolina, 27609
Research Site
Rapid City, South Dakota, 57701
Research Site
Richmond, Virginia, 23219
Research Site
Richmond, Virginia, 23294
Research Site
Roanoke, Virginia, 24014
Research Site
Rochester, New York, 14609
Research Site
Roseville, California, 95661
Research Site
Sacramento, California, 95816
Research Site
Safety Harbor, Florida, 34695
Research Site
Saginaw, Michigan, 48601
Research Site
Saginaw, Michigan, 48604
Research Site
Saint Cloud, Minnesota, 56303
Research Site
Saint Paul, Minnesota, 55102
Research Site
Salisbury, Maryland, 21804
Research Site
San Antonio, Texas, 78229
Research Site
San Diego, California, 92103
Research Site
San Diego, California, 92161
Research Site
San Pedro, California, 90732
Research Site
Sandusky, Ohio, 44870
Research Site
Sanford, Florida, 32771
Research Site
Santa Ana, California, 92704
Research Site
Sarasota, Florida, 34232
Research Site
Sarasota, Florida, 34239
Research Site
Savannah, Georgia, 31406
Research Site
Seaford, Delaware, 19973
Research Site
Seattle, Washington, 98104
Research Site
Seattle, Washington, 98195
Research Site
Selah, Washington, 98942
Research Site
Sellersville, Pennsylvania, 18960
Research Site
Slidell, Louisiana, 70458
Research Site
Springfield, Massachusetts, 01199
Research Site
Springfield, Ohio, 45505
Research Site
St Louis, Missouri, 63117
Research Site
St Louis, Missouri, 63128
Research Site
St. Petersburg, Florida, 33709
Research Site
St. Petersburg, Florida, 33713
Research Site
Statesville, North Carolina, 28625
Research Site
Stony Brook, New York, 11794
Research Site
Suffolk, Virginia, 23435
Research Site
Sugar Land, Texas, 77478
Research Site
Suwanee, Georgia, 30024
Research Site
Syracuse, New York, 13202
Research Site
Tabor City, North Carolina, 28463
Research Site
Tampa, Florida, 33614
Research Site
Tarzana, California, 91356
Research Site
Thousand Oaks, California, 91360
Research Site
Toledo, Ohio, 43608
Research Site
Toledo, Ohio, 43615
Research Site
Toledo, Ohio, 43623
Research Site
Tomball, Texas, 77375
Research Site
Torrance, California, 90502
Research Site
Torrance, California, 90503
Research Site
Towson, Maryland, 21204
Research Site
Traverse City, Michigan, 49684
Research Site
Troy, New York, 12180
Research Site
Tucson, Arizona, 85712
Research Site
Tucson, Arizona, 85723
Research Site
Tullahoma, Tennessee, 37388
Research Site
Tulsa, Oklahoma, 74133

Other trials in United States

United Kingdom76 sites

Research Site
Aberdeen, AB25 2ZN
Research Site
Addlestone, KT15 2BH
Research Site
Arnsley, S75 2EP
Research Site
Basildon, SS16 5NL
Research Site
Belfast, BT12 6BA
Research Site
Belfast, BT13 3BW
Research Site
Belfast, BT16 1RH
Research Site
Belfast, BT7 2EB
Research Site
Birmingham, B15 2SQ
Research Site
Birmingham, B18 7QH
Research Site
Blackpool, FY3 8NR
Research Site
Bournemouth, BH7 7DW
Research Site
Bury St Edmunds, IP33 2QZ
Research Site
Canterbury, CT1 3NG
Research Site
Cardiff, CF14 5GJ
Research Site
Cardiff, CF4 4XW
Research Site
Chesterfield, S40 4AA
Research Site
Chippenham, SN15 2SB
Research Site
Chorley, PR7 7NA
Research Site
Colchester, CO4 5JL
Research Site
Cottingham, HU16 5JQ
Research Site
Coventry, CV4 7AL
Research Site
Dundee, DD1 9SY
Research Site
Edinburgh, EH16 4SB
Research Site
Glasgow, G20 0SP
Research Site
Glasgow, G45 9AW
Research Site
Glasgow, G51 4TF
Research Site
Harrow, HA1 3UJ
Research Site
Haxey, Doncaster, DN9 2HY
Research Site
Hayle, TR27 5DT
Research Site
Hexham, NE46 1QJ
Research Site
Hitchin, SG4 9TH
Research Site
Inverness, IV2 3JH
Research Site
Leeds, LS1 3EX
Research Site
Leicester, LE3 9QP
Research Site
Liverpool, L22 0LG
Research Site
Liverpool, L7 8XP
Research Site
Liverpool, L9 7AL
Research Site
London, EC1M 6BQ
Research Site
London, SE1 7EH
Research Site
London, W12 0HS
Research Site
Luton, LU4 0DZ
Research Site
Manchester, M15 6SX
Research Site
Manchester, M23 9LT
Research Site
Metropolitan Borough of Wirral, CH49 5PE
Research Site
Middlesbrough, TS4 3BW
Research Site
Newport, PO30 5TG
Research Site
Northampton, NN1 5BD
Research Site
Nottingham, NG5 1PB
Research Site
Nuneaton, CV10 7DJ
Research Site
Penzance, TR18 2RE
Research Site
Penzance, TR18 4EL
Research Site
Penzance, TR19 7HX
Research Site
Plymouth, PL6 8DH
Research Site
Portsmouth, PO6 3LY
Research Site
Reading, RG2 0TF
Research Site
Rotherham, S60 2UD
Research Site
Royal Leamington Spa, CV34 4RA
Research Site
Rugby, CV22 5PX
Research Site
Saint Leonards-on-Sea, TN37 7RD
Research Site
Sandbach, CW11 1EQ
Research Site
Sheffield, S5 7AU
Research Site
St Austell, PL26 7RL
Research Site
Stevenage, SG1 4AB
Research Site
Stoke-on-Trent, ST4 6DG
Research Site
Swansea, SA2 8PP
Research Site
Telford, TF1 6TF
Research Site
Torquay, TQ2 7AA
Research Site
Welwyn Garden City, AL7 4HQ
Research Site
West Bromwich, B71 4HJ
Research Site
Whitby, YO21 1SD
Research Site
Wiltshire, BA15 1DQ
Research Site
Wolverhampton, WV10 0QP
Research Site
Worcester, WR5 1DD
Research Site
Wrexham, LL13 7TD
Research Site
York, YO31 8HE

Other trials in United Kingdom

Japan65 sites

Research Site
Asahikawa-shi, Hokkaido, 070-0054
Research Site
Bunkyo-ku, Tokyo, 113-8431
Research Site
Chiba, Chiba, 260-8606
Research Site
Chikushi-gun, Fukuoka, 811-1244
Research Site
Chikushino-shi, Fukuoka, 818-8516
Research Site
Chuo-ku, Tokyo, 103-0027
Research Site
Chuo-shi, Yamanashi, 409-3898
Research Site
Fujisawa-shi, Kanagawa, 251-8550
Research Site
Fukuoka, Fukuoka, 814-0180
Research Site
Fukuoka, Fukuoka, 814-8522
Research Site
Hachioji-shi, Tokyo, 192-0918
Research Site
Hamada-shi, Shimane, 697-8511
Research Site
Higashisonogi-gun, Nagasaki, 859-3615
Research Site
Himeji-shi, Hyōgo, 672-8043
Research Site
Ichinomiya-shi, Aichi-ken, 491-8551
Research Site
Itoshima-shi, Fukuoka, 819-1104
Research Site
Kanazawa, Ishikawa-ken, 920-8650
Research Site
Kasugai-shi, Aichi-ken, 487-0031
Research Site
Kawaguchi-shi, Saitama, 332-8558
Research Site
Kobe, Hyōgo, 654-0155
Research Site
Koga-shi, Fukuoka, 811-3195
Research Site
Komatsushima-shi, Tokushima, 773-8502
Research Site
Koriyama-shi, Fukushima, 963-8052
Research Site
Kumamoto, Kumamoto, 860-8556
Research Site
Kure-shi, Hiroshima, 737-0023
Research Site
Kurume-shi, Fukuoka, 830-0011
Research Site
Kurume-shi, Fukuoka, 830-8577
Research Site
Kusatsu-shi, Shiga, 525-8585
Research Site
Kyoto, Kyoto, 615-0035
Research Site
Matsudo-shi, Chiba, 271-0077
Research Site
Musashimurayama-shi, Tokyo, 208-0011
Research Site
Nagasaki, Nagasaki, 850-8555
Research Site
Nagoya, Aichi-ken, 451-8511
Research Site
Nagoya, Aichi-ken, 455-8530
Research Site
Nagoya, Aichi-ken, 457-8511
Research Site
Nagoya, Aichi-ken, 460-0001
Research Site
Niihama-shi, Ehime, 792-8586
Research Site
Odawara-shi, Kanagawa, 250-8558
Research Site
Ōita, Oita Prefecture, 870-0263
Research Site
Okawa-shi, Fukuoka, 831-0016
Research Site
Okayama, Okayama-ken, 702-8055
Research Site
Okinawa-shi, Okinawa, 904-8585
Research Site
Omura-shi, Nagasaki, 856-8562
Research Site
Osaka, Osaka, 530-0001
Research Site
Osaka, Osaka, 530-8480
Research Site
Osaka, Osaka, 543-0035
Research Site
Osaka, Osaka, 550-0022
Research Site
Otake-shi, Hiroshima, 739-0651
Research Site
Saga, Saga-ken, 840-8571
Research Site
Saga, Saga-ken, 849-0917
Research Site
Sagamihara-shi, Kanagawa, 252-0375
Research Site
Saijo-shi, Ehime, 793-0030
Research Site
Sanuki-shi, Kagawa-ken, 769-2393
Research Site
Sapporo, Hokkaido, 060-0031
Research Site
Sendai, Miyagi, 983-8520
Research Site
Shimajiri-gun, Okinawa, 901-0493
Research Site
Sunto-gun, Shizuoka, 411-8611
Research Site
tabashi City, Tokyo, 173-8606
Research Site
tabashi City, Tokyo, 173-8610
Research Site
Tachikawa-shi, Tokyo, 190-0014
Research Site
Toride-shi, Ibaraki, 302-0022
Research Site
Toyohashi, Aichi-ken, 440-8510
Research Site
Tsukuba, Ibaraki, 305-8558
Research Site
Urasoe-shi, Okinawa, 901-2132
Research Site
Yokohama, Kanagawa, 245-8575

Other trials in Japan

Poland54 sites

Research Site
Bielsko-Biala, 43-316
Research Site
Bydgoszcz, 85-094
Research Site
Gdansk, 80-542
Research Site
Gdansk, 80-952
Research Site
Gdynia, 81-384
Research Site
Gdynia, 81-402
Research Site
Gdynia, 81-472
Research Site
Giżycko, 11-500
Research Site
Jelenia Góra, 58-506
Research Site
Katowice, 40-018
Research Site
Katowice, 40-040
Research Site
Katowice, 40-084
Research Site
Kielce, 25-020
Research Site
Krakow, 30-001
Research Site
Krakow, 30-347
Research Site
Krakow, 31-202
Research Site
Krakow, 31-216
Research Site
Krakow, 31-315
Research Site
Krakow, 32-082
Research Site
Lodz, 90-368
Research Site
Lodz, 90-549
Research Site
Lodz, 91-347
Research Site
Lodz, 93-530
Research Site
Lublin, 20-045
Research Site
Lublin, 20-080
Research Site
Lublin, 20-857
Research Site
Nowa Sól, 67-100
Research Site
Nysa, 48-300
Research Site
Olsztyn, 10-010
Research Site
Płock, 09-402
Research Site
Poznan, 60-702
Research Site
Poznan, 61-113
Research Site
Poznan, 61-853
Research Site
Pszczyna, 43-200
Research Site
Puławy, 24-100
Research Site
Ruda Śląska, 41-709
Research Site
Skierniewice, 96-100
Research Site
Starogard Gdański, 83-200
Research Site
Staszów, 28-200
Research Site
Świdnik, 21-040
Research Site
Tarnów, 33-100
Research Site
Torun, 87-100
Research Site
Warsaw, 01-192
Research Site
Warsaw, 01-809
Research Site
Warsaw, 02-097
Research Site
Warsaw, 02-507
Research Site
Warsaw, 04-628
Research Site
Warsaw, 04-730
Research Site
Warsaw, 04-749
Research Site
Włocławek, 87-800
Research Site
Wroclaw, 50-088
Research Site
Wroclaw, 50-349
Research Site
Wroclaw, 51-685
Research Site
Zamość, 22-400

Other trials in Poland

Czechia52 sites

Research Site
Benátky nad Jizerou, 294 71
Research Site
Benešov, 256 01
Research Site
Beroun, 266 01
Research Site
Bílovec, 743 01
Research Site
Brandýs nad Labem, 250 01
Research Site
Brno, 602 00
Research Site
Brno, 603 00
Research Site
Brno, 625 00
Research Site
Brno, 636 00
Research Site
Brno, 638 00
Research Site
Brno, 656 91
Research Site
České Budějovice, 370 04
Research Site
Český Krumlov, 381 01
Research Site
Chomutov, 430 02
Research Site
Havlíčkův Brod, 580 22
Research Site
Hodonín, 695 01
Research Site
Hradec Králové, 500 02
Research Site
Hranice, 753 22
Research Site
Jihlava, 586 01
Research Site
Kladno, 272 59
Research Site
Klatovy IV, 339 01
Research Site
Kutná Hora, 284 01
Research Site
Liberec, 460 63
Research Site
Litoměřice, 412 01
Research Site
Litomyšl, 570 14
Research Site
Milevsko, 399 01
Research Site
Mladá Boleslav, 293 01
Research Site
Mohelnice, 789 85
Research Site
Moravské Budějovice, 676 02
Research Site
Nymburk, 288 01
Research Site
Olomouc, 779 00
Research Site
Ostrava, 728 80
Research Site
Ostrava-Poruba, 708 00
Research Site
Pardubice, 530 02
Research Site
Pilsen, 305 99
Research Site
Polička, 572 01
Research Site
Prachatice, 383 01
Research Site
Prague, 101 00
Research Site
Prague, 128 08
Research Site
Prague, 130 00
Research Site
Prague, 140 21
Research Site
Prague, 140 59
Research Site
Prague, 150 06
Research Site
Prague, 158 00
Research Site
Praha 5 - Smichov, 150 00
Research Site
Přerov, 750 02
Research Site
Pribram VIII, 261 01
Research Site
Svitavy, 568 25
Research Site
Teplice, 415 01
Research Site
Uherské Hradiště, 686 01
Research Site
Zábřeh nad Odrou, 700 30
Research Site
Znojmo, 669 02

Other trials in Czechia

Canada46 sites

Research Site
Brampton, Ontario, L6Z 4N5
Research Site
Calgary, Alberta, T2N 4Z6
Research Site
Cambridge, Ontario, N1R 6V6
Research Site
Chicoutimi, Quebec, G7H 7K9
Research Site
Gatineau, Quebec, J8Y 6S8
Research Site
Granby, Quebec, J2G 8Z9
Research Site
Greenfield Park, Quebec, J4V 2G8
Research Site
Halifax, Nova Scotia, B3H 3A7
Research Site
Hamilton, Ontario, L8L 2X2
Research Site
Kelowna, British Columbia, V1Y 1V6
Research Site
Lachine, Quebec, H8S 2E4
Research Site
London, Ontario, N6A 5K8
Research Site
London, Ontario, N6C 0A7
Research Site
Longueuil, Quebec, J4M 2X1
Research Site
Montreal, Quebec, H1T 3Y7
Research Site
Montreal, Quebec, H1Y 3L1
Research Site
Montreal, Quebec, H2W 1R7
Research Site
Montreal, Quebec, H2W 1T8
Research Site
Montreal, Quebec, H3G 1A4
Research Site
Montreal, Quebec, H4A 3J1
Research Site
New Westminster, British Columbia, V3L 3W4
Research Site
Newmarket, Ontario, L3Y 5G8
Research Site
Newmarket, Ontario, L3Y 8C3
Research Site
Oshawa, Ontario, L1J 2J9
Research Site
Oshawa, Ontario, L1J 2K1
Research Site
Ottawa, Ontario, K1Y 4W7
Research Site
Peterborough, Ontario, K9J 0B2
Research Site
Pointe-Claire, Quebec, H9R 3J1
Research Site
Québec, Quebec, G1V 4G5
Research Site
Québec, Quebec, G1V 4W2
Research Site
Regina, Saskatchewan, S4P 0W5
Research Site
Saint-Charles-Borromée, Quebec, J6E 6J2
Research Site
Saint-Jean-sur-Richelieu, Quebec, J3A 1C3
Research Site
Saint-Jérôme, Quebec, J7Z 5T3
Research Site
Sarnia, Ontario, N7T 4X3
Research Site
Scarborough Village, Ontario, M1E 5E9
Research Site
Scarborough Village, Ontario, M1P 2T7
Research Site
St. John's, Newfoundland and Labrador, A1A 3R5
Research Site
St. John's, Newfoundland and Labrador, A1B 3V6
Research Site
Strathroy, Ontario, N7G 1Y7
Research Site
Terrebonne, Quebec, J6V 2H2
Research Site
Thunder Bay, Ontario, P7B 6V4
Research Site
Toronto, Ontario, M5C 2T2
Research Site
Toronto, Ontario, M5T 3A9
Research Site
Vancouver, British Columbia, V6Z 1Y6
Research Site
Westmout, Quebec, H3Z 1E5

Other trials in Canada

China37 sites

Research Site
Baotou, Inner Mongolia, 014010
Research Site
Beijing, Beijing Municipality, 100037
Research Site
Beijing, Beijing Municipality, 100191
Research Site
Beijing, 100020
Research Site
Changchun, Jilin, 130011
Research Site
Changchun, Jilin, 130021
Research Site
Changchun, Jilin, 130033
Research Site
Changde, Hunan, 415003
Research Site
Changsha, Hunan, 410004
Research Site
Changsha, Hunan, 410005
Research Site
Changsha, Hunan, 410008
Research Site
Changsha, Hunan, 410013
Research Site
Dalian, Liaoning, 116027
Research Site
Guangzhou, Guangdong, 510080
Research Site
Hangzhou, Zhejiang, 310013
Research Site
Harbin, Heilongjiang, 150001
Research Site
Hohhot, Inner Mongolia, 010020
Research Site
Linhai, Zhejiang, 317000
Research Site
Ningbo, Zhejiang, 315010
Research Site
Qingdao, Shandong, 266003
Research Site
Shenyang, Liaoning, 110016
Research Site
Siping, Jilin, 136000
Research Site
Suzhou, Jiangsu, 215000
Research Site
Taiyuan, Shanxi, 030009
Research Site
Tianjin, Tianjin Municipality, 300052
Research Site
Tianjin, Tianjin Municipality, 300120
Research Site
Tianjin, 300211
Research Site
Ürümqi, Xinjiang, 830054
Research Site
Wenzhou, Zhejiang, 325000
Research Site
Wuhan, Hubei, 430014
Research Site
Wuhan, Hubei, 430030
Research Site
Wuxi, Jiangsu, 214023
Research Site
Xiangtan, Hunan, 411100
Research Site
Xuzhou, Jiangsu, 221006
Research Site
Yinchuan, Ningxia, 750004
Research Site
Zhengzhou, Henan, 450052
Research Site
Zhuzhou, Hunan, 412000

Other trials in China

Germany33 sites

Research Site
Bad Krozingen, 79189
Research Site
Berlin, 10787
Research Site
Berlin, 12351
Research Site
Berlin, 12559
Research Site
Berlin, 13353
Research Site
Bochum, 44787
Research Site
Cologne, 50937
Research Site
Demmin, 17109
Research Site
Dortmund, 44137
Research Site
Dresden, 01307
Research Site
Düsseldorf, 40210
Research Site
Frankfurt am Main, 60596
Research Site
Giessen, 35392
Research Site
Hamburg, 20099
Research Site
Hamburg, 20246
Research Site
Hanover, 30159
Research Site
Heidelberg, 69120
Research Site
Ingelheim, 55218
Research Site
Kassel, 34121
Research Site
Lahr, 77933
Research Site
Leipzig, 04103
Research Site
Limburg, 65549
Research Site
Magdeburg, 39120
Research Site
Mainz, 55131
Research Site
Mannheim, 68165
Research Site
Marburg, 35043
Research Site
München, 80636
Research Site
München, 80638
Research Site
Regensburg, 93053
Research Site
Stuttgart, 70376
Research Site
Ulm, 89081
Research Site
Witten, 58455
Research Site
Wuppertal, 42117

Other trials in Germany

Netherlands33 sites

Research Site
Alkmaar, 1815 JD
Research Site
Almelo, 7609 PP
Research Site
Amstelveen, 1186 AM
Research Site
Amsterdam, 1061 AE
Research Site
Amsterdam, 1091 AC
Research Site
Arnhem, 6815 AD
Research Site
Beverwijk, 1942 LE
Research Site
Den Helder, 1782 GZ
Research Site
Deventer, 7416 SE
Research Site
Doetinchem, 7009 BL
Research Site
Ede, 6716 RP
Research Site
Eindhoven, 5623 EJ
Research Site
Eindhoven, 5631 BM
Research Site
Goes, 4462 RA
Research Site
Gorinchem, 4204 AA
Research Site
Gouda, 2803 HH
Research Site
Harderwijk, 3844 DG
Research Site
Helmond, 5707 HA
Research Site
Hoogeveen, 7909 AA
Research Site
Hoorn, 1624 NP
Research Site
Leiden, 2333 ZA
Research Site
Leiden, 2334 CK
Research Site
Nieuwegein, 3435 CM
Research Site
Nijmegen, 6532 SZ
Research Site
Purmerend, 1440 AG
Research Site
Rotterdam, 3045 PM
Research Site
Rotterdam, 3079 DZ
Research Site
Sneek, 8601 ZK
Research Site
Tiel, 4002 WP
Research Site
Tilburg, 5042 AD
Research Site
Uden, 5406 PT
Research Site
Veldhoven, 5504 DB
Research Site
Venlo, 5912 BL

Other trials in Netherlands

Russia33 sites

Research Site
Barnaul, 656038
Research Site
Barnaul, 656055
Research Site
Ivanovo, 153012
Research Site
Izhevsk, 426063
Research Site
Kemerovo, 650002
Research Site
Kemerovo, 650099
Research Site
Kirov, 610014
Research Site
Moscow, 101990
Research Site
Moscow, 111020
Research Site
Moscow, 111539
Research Site
Moscow, 117292
Research Site
Moscow, 117342
Research Site
Moscow, 119620
Research Site
Moscow, 121552
Research Site
Moscow, 129090
Research Site
Nizhny Novgorod, 603076
Research Site
Novosibirsk, 630047
Research Site
Novosibirsk, 630089
Research Site
Omsk, 644018
Research Site
Pushkin, 196601
Research Site
Saint Petersburg, 191015
Research Site
Saint Petersburg, 192289
Research Site
Saint Petersburg, 194156
Research Site
Saint Petersburg, 195112
Research Site
Saint Petersburg, 197022
Research Site
Saint Petersburg, 197341
Research Site
Saint Petersburg, 198205
Research Site
Saint Petersburg, 199106
Research Site
Saratov, 410054
Research Site
Tomsk, 634012
Research Site
Tyumen, 625000
Research Site
Yekaterinburg, 620102
Research Site
Yekaterinburg, 620144

Other trials in Russia

France32 sites

Research Site
Besançon, 25030
Research Site
Brest, 29200
Research Site
Chambray-lès-Tours, 37170
Research Site
Clermont-Ferrand, 63000
Research Site
Créteil, 94010
Research Site
Dijon, 21079
Research Site
Le Coudray, 28630
Research Site
Lille, 59037
Research Site
Lyon, 69007
Research Site
Marseille, 13285
Research Site
Metz, 57085
Research Site
Montpellier, 34094
Research Site
Montpellier, 34295
Research Site
Nantes, 44093
Research Site
Nantes, 44202
Research Site
Nice, 06000
Research Site
Nîmes, 30029
Research Site
Orléans, 45067
Research Site
Paris, 75010
Research Site
Paris, 75013
Research Site
Paris, 75015
Research Site
Pau, 64000
Research Site
Perpignan, 66046
Research Site
Pessac, 33604
Research Site
Poitiers, 86000
Research Site
Reims, 51092
Research Site
Rennes, 35033
Research Site
Saint-Priest-en-Jarez, 42270
Research Site
Strasbourg, 67091
Research Site
Toulouse, 31059
Research Site
Vandœuvre-lès-Nancy, 54511
Research Site
Vesoul, 70014

Other trials in France

South Africa28 sites

Research Site
Alberton, Gauteng, 1449
Research Site
Alberton, Gauteng, 1450
Research Site
Bloemfontein, Free State, 9301
Research Site
Boksburg, Gauteng, 1459
Research Site
Cape Town, 7405
Research Site
Cape Town, 7530
Research Site
Centurion, Gauteng, 0157
Research Site
Durban, KwaZulu-Natal, 4001
Research Site
Durban, KwaZulu-Natal, 4321
Research Site
eManzimtoti, KwaZulu-Natal, 4126
Research Site
Johannesburg, Gauteng, 1724
Research Site
Johannesburg, Gauteng, 2196
Research Site
Kempton Park, 1619
Research Site
Kuils River, Western Cape, 7580
Research Site
Midrand, Gauteng, 1685
Research Site
Paarl, Western Cape, 7646
Research Site
Parow, Western Cape, 7505
Research Site
Port Elizabeth, Eastern Cape, 6001
Research Site
Pretoria, Gauteng, 0040
Research Site
Pretoria, Gauteng, 0087
Research Site
Pretoria, Gauteng, 0158
Research Site
Pretoria, Gauteng, 0184
Research Site
Pretoria West, Gauteng, 0183
Research Site
Somerset West, Western Cape, 7130
Research Site
Soweto, Gauteng, 2013
Research Site
Sunninghill, Gauteng, 2157
Research Site
Tongaat, KwaZulu-Natal, 4400
Research Site
Worcester, Western Cape, 6850

Other trials in South Africa

Brazil26 sites

Research Site
Belo Horizonte, Minas Gerais, 30150-240
Research Site
Brasília, Federal District, 71625-009
Research Site
Campina Grande do Sul, Paraná, 83430-000
Research Site
Campinas, São Paulo, 13010-001
Research Site
Campinas, São Paulo, 13059-740
Research Site
Canoas, Rio Grande do Sul, 92425-900
Research Site
Curitiba, Paraná, 80010-030
Research Site
Curitiba, Paraná, 80730-150
Research Site
Fortaleza, Ceará, 60430-350
Research Site
Goiânia, Goiás, 74223-130
Research Site
Passo Fundo, Rio Grande do Sul, 99010-080
Research Site
Porto Alegre, Rio Grande do Sul, 90020-090
Research Site
Porto Alegre, Rio Grande do Sul, 90035-001
Research Site
Porto Alegre, Rio Grande do Sul, 90035-903
Research Site
Porto Alegre, Rio Grande do Sul, 90610-000
Research Site
Porto Alegre, Rio Grande do Sul, 90620-001
Research Site
Porto Alegre, Rio Grande do Sul, 90880-480
Research Site
Porto Alegre, Rio Grande do Sul, 91350-200
Research Site
Rio de Janeiro, 22271-100
Research Site
São José do Rio Preto, São Paulo, 15015-210
Research Site
São Paulo, São Paulo, 01244-030
Research Site
São Paulo, São Paulo, 04004-030
Research Site
São Paulo, 04040-000
Research Site
São Paulo, 04266-010
Research Site
São Paulo, 05403-000
Research Site
Vitória, Espírito Santo, 29042-751

Other trials in Brazil

Hungary24 sites

Research Site
Balatonfüred, 8230
Research Site
Békéscsaba, 5600
Research Site
Berettyóújfalu, 4100
Research Site
Budapest, 1027
Research Site
Budapest, 1036
Research Site
Budapest, 1085
Research Site
Budapest, 1096
Research Site
Budapest, 1122
Research Site
Budapest, 1125
Research Site
Budapest, 1134
Research Site
Cegléd, 2700
Research Site
Debrecen, 4032
Research Site
Gyöngyös, 3200
Research Site
Gyula, 5700
Research Site
Kaposvár, 7400
Research Site
Kecskemét, 6000
Research Site
Komárom, 2921
Research Site
Miskolc, 3529
Research Site
Nyíregyháza, 4400
Research Site
Pécs, 7624
Research Site
Szeged, 6725
Research Site
Szekszárd, 7100
Research Site
Szolnok, 5004
Research Site
Zalaegerszeg, 8900

Other trials in Hungary

Argentina23 sites

Research Site
Bahía Blanca, Buenos Aires, B8000FTD
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, 1209
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1093AAS
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1128AAF
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1426EGR
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1428AQK
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1430CKE
Research Site
Córdoba, Córdoba Province, X5000BNB
Research Site
Córdoba, Córdoba Province, X5000EPU
Research Site
Córdoba, Córdoba Province, X5002AOQ
Research Site
Córdoba, Córdoba Province, X5016KEH
Research Site
Córdoba, X5003DCE
Research Site
Corrientes, W3400AMZ
Research Site
La Plata, Buenos Aires, B1902AGY
Research Site
La Plata, Buenos Aires, B1902COS
Research Site
Mar del Plata, Buenos Aires, B7600FZN
Research Site
Mar del Plata, Buenos Aires, B7602CBM
Research Site
Quilmes, Buenos Aires, B1878GEG
Research Site
Rosario, Santa Fe Province, S2000CVD
Research Site
Salta, A4400ANG
Research Site
Salta, A4400CRC
Research Site
San Miguel de Tucumán, Tucumán Province, T4000IAF
Research Site
San Miguel de Tucumán, Tucumán Province, T4000ICL

Other trials in Argentina

Ukraine22 sites

Research Site
Cherkasy, 18009
Research Site
Ivano-Frankivsk, 76018
Research Site
Kharkiv, 61002
Research Site
Kharkiv, 61018
Research Site
Kharkiv, 61039
Research Site
Kharkiv, 61106
Research Site
Kharkiv, 61176
Research Site
Kyiv, 01023
Research Site
Kyiv, 02002
Research Site
Kyiv, 02091
Research Site
Kyiv, 02232
Research Site
Kyiv, 02660
Research Site
Kyiv, 03049
Research Site
Kyiv, 03680
Research Site
Kyiv, 04114
Research Site
Luhansk, 91045
Research Site
Uzhhorod, 88000
Research Site
Vinnytsia, 21018
Research Site
Vinnytsia, 21029
Research Site
Zaporizhzhya, 69000
Research Site
Zaporizhzhya, 69035
Research Site
Zaporizhzhya, 69600

Other trials in Ukraine

Australia21 sites

Research Site
Adelaide, South Australia, 5000
Research Site
Ashford, South Australia, 5035
Research Site
Ashford, South Australia, 5036
Research Site
Auchenflower, Queensland, 4066
Research Site
Box Hill, Victoria, 3128
Research Site
Camperdown, New South Wales, 2050
Research Site
Concord, New South Wales, 2139
Research Site
Epping, Victoria, 3076
Research Site
Footscray, Victoria, 3011
Research Site
Fullarton, South Australia, 5063
Research Site
Geelong, Victoria, 3220
Research Site
Heidelberg, Victoria, 3084
Research Site
Herston, Queensland, 4029
Research Site
Hobart, Tasmania, 7000
Research Site
Kogarah, New South Wales, 2217
Research Site
Liverpool, New South Wales, 2170
Research Site
Nedlands, Western Australia, 6009
Research Site
Woden, Australian Capital Territory, 2605
Research Site
Woodville South, South Australia, 5011
Research Site
Woolloongabba, New South Wales, 4102
Research Site
Woolloongabba, Queensland, 4102

Other trials in Australia

Slovakia21 sites

Research Site
Bánovce nad Bebravou, 957 01
Research Site
Bardejov, 085 01
Research Site
Bratislava, 811 04
Research Site
Bratislava, 811 08
Research Site
Bratislava, 833 48
Research Site
Brezno, 977 42
Research Site
Dolný Kubín, 026 01
Research Site
Košice, 040 01
Research Site
Košice, 040 22
Research Site
Lučenec, 984 01
Research Site
Martin, 036 59
Research Site
Moldava nad Bodvou, 045 01
Research Site
Nitra, 949 01
Research Site
Nové Zámky, 940 01
Research Site
Prešov, 080 01
Research Site
Rimavská Sobota, 979 01
Research Site
Rožňava, 048 01
Research Site
Snina, 069 01
Research Site
Svidník, 089 01
Research Site
Trenčín, 911 01
Research Site
Trnava, 917 01

Other trials in Slovakia

Italy20 sites

Research Site
Ascoli Piceno, 63100
Research Site
Bergamo, 24127
Research Site
Bologna, 40138
Research Site
Chieti, 66100
Research Site
Colleferro RM, 00034
Research Site
Cortona AR, 52044
Research Site
Florence, 50139
Research Site
L’Aquila, 67100
Research Site
Milan, 20138
Research Site
Milan, 20162
Research Site
Naples, 80131
Research Site
Palermo, 90126
Research Site
Parma, 43100
Research Site
Pavia, 27100
Research Site
Perugia, 06129
Research Site
Pisa, 56124
Research Site
Roma, 00161
Research Site
Roma, 00168
Research Site
Sanremo (IM), 18038
Research Site
Siena, 53100

Other trials in Italy

Greece19 sites

Research Site
Alexandroupoli, 68100
Research Site
Athens, 10676
Research Site
Athens, 11521
Research Site
Athens, 11527
Research Site
Athens, 12462
Research Site
Athens, 14233
Research Site
Athens, 14561
Research Site
Athens, 15123
Research Site
Athens, 16673
Research Site
Athens, 17674
Research Site
Chalcis, 34100
Research Site
Heraklion, 71110
Research Site
Ioannina, 45500
Research Site
Larissa, 41110
Research Site
Nikaia, Piraeus, 18454
Research Site
Piraeus, 18536
Research Site
Rhodes, 85100
Research Site
Thessaloniki, 54636
Research Site
Thessaloniki, 54642

Other trials in Greece

India19 sites

Research Site
Ahmedabad, Gujarat, 380 008
Research Site
Ahmedabad, Gujarat, 380 016
Research Site
Ahmedabad, Gujarat, 380 054
Research Site
Ahmedabad, Gujarat, 380 060
Research Site
Belagavi, Karnataka, 590 010
Research Site
Gurgaon, Haryana, 122 001
Research Site
Kolkata, West Bengal, 700 020
Research Site
Lucknow, Uttar Pradesh, 226 003
Research Site
Mumbai, Maharashtra, 400 007
Research Site
Mumbai, Maharashtra, 400 008
Research Site
Mumbai, Maharashtra, 400 022
Research Site
Mysore, Karnataka, 570 001
Research Site
Nagpur, Maharashtra, 440 003
Research Site
New Delhi, National Capital Territory of Delhi, 110 002
Research Site
Pune, Maharashtra, 411 005
Research Site
Pune, Maharashtra, 411 006
Research Site
Pune, Maharashtra, 411 019
Research Site
Vadodara, Gujarat, 390 001
Research Site
Vijayawada, Andhra Pradesh, 520 008

Other trials in India

Sweden19 sites

Research Site
Bollnäs, 821 81
Research Site
Eksjö, 575 81
Research Site
Eskilstuna, 631 88
Research Site
Falun, 791 82
Research Site
Helsingborg, 251 87
Research Site
Jönköping, 551 85
Research Site
Linköping, 581 85
Research Site
Luleå, 971 80
Research Site
Lund, 221 85
Research Site
Lund, 222 21
Research Site
Örebro, 701 85
Research Site
Östersund, 831 83
Research Site
Stockholm, 111 57
Research Site
Stockholm, 118 83
Research Site
Stockholm, 141 86
Research Site
Stockholm, 171 76
Research Site
Uddevalla, 451 50
Research Site
Umeå, 901 85
Research Site
Västerås, 721 89

Other trials in Sweden

Mexico17 sites

Research Site
Aguascalientes, 20230
Research Site
Chihuahua City, 31217
Research Site
Culiacán, Sinaloa, 80230
Research Site
Guadalajara, Jalisco, 44150
Research Site
Guadalajara, Jalisco, 44210
Research Site
Guadalajara, Jalisco, 44340
Research Site
Guadalajara, Jalisco, 44380
Research Site
Guadalajara, Jalisco, 44600
Research Site
León, Guanajuato, 37520
Research Site
Mexico City, Mexico City, 03800
Research Site
Mexico City, Mexico City, 14380
Research Site
Monterrey, Nuevo León, 64718
Research Site
Querétaro City, Querétaro, 76000
Research Site
San Luis Potosí City, San Luis Potosí, 78240
Research Site
Tampico, Tamaulipas, 89000
Research Site
Torreón, Coahuila, 27000
Research Site
Xalapa, Veracruz, 91193

Other trials in Mexico

South Korea17 sites

Research Site
Busan, Seo-gu, 602-715
Research Site
Daejeon, 301-723
Research Site
Daejeon, 371-718
Research Site
Goyang-si, Gyeonggi-do, 411-706
Research Site
Gwangju, 501-757
Research Site
Seongnam-si, 463-707
Research Site
Seoul, 110-746
Research Site
Seoul, 120-752
Research Site
Seoul, 130-872
Research Site
Seoul, 135-700
Research Site
Seoul, 135-710
Research Site
Seoul, 137-701
Research Site
Seoul, 138-736
Research Site
Seoul, 152-703
Research Site
Seoul, 156-707
Research Site
Seoul, 158-710
Research Site
Suwon, 443-380

Other trials in South Korea

Belgium16 sites

Research Site
Aalst, 9300
Research Site
Antwerp, 2020
Research Site
Antwerp, 2060
Research Site
Blankenberge, 8370
Research Site
Bonheiden, 2820
Research Site
Brussels, 1020
Research Site
Brussels, 1070
Research Site
Brussels, 1200
Research Site
Ghent, 9000
Research Site
Gozée, 6534
Research Site
Ieper, 8900
Research Site
La Louvière, 7100
Research Site
Liège, 4000
Research Site
Lodelinsart, 6042
Research Site
Natoye, 5360
Research Site
Turnhout, 2300

Other trials in Belgium

Romania16 sites

Research Site
Bucharest, 010242
Research Site
Bucharest, 011601
Research Site
Bucharest, 020054
Research Site
Bucharest, 020125
Research Site
Bucharest, 021659
Research Site
Bucharest, 030463
Research Site
Bucharest, 042122
Research Site
Cluj-Napoca, 400347
Research Site
Craiova, 200147
Research Site
Iași, 700503
Research Site
Iași, 700547
Research Site
Iași, 700661
Research Site
Oradea, 410169
Research Site
Timișoara, 300079
Research Site
Timișoara, 300158
Research Site
Timișoara, 300736

Other trials in Romania

Denmark14 sites

Research Site
Aalborg, 9000
Research Site
Aarhus N, 8200
Research Site
Ballerup Municipality, 2750
Research Site
Copenhagen, 2400
Research Site
Esbjerg, 6700
Research Site
Glostrup Municipality, 2600
Research Site
Hvidovre, 2650
Research Site
København S, 2300
Research Site
Køge, 4600
Research Site
Odense, 5000
Research Site
Roskilde, 4000
Research Site
Svendborg, 5700
Research Site
Vejle, 7100
Research Site
Viborg, 8800

Other trials in Denmark

Bulgaria12 sites

Research Site
Haskovo, 6300
Research Site
Kazanlak, 6100
Research Site
Pazardzhik, 4700
Research Site
Pleven, 5800
Research Site
Plovdiv, 4002
Research Site
Sofia, 1309
Research Site
Sofia, 1407
Research Site
Sofia, 1431
Research Site
Sofia, 1527
Research Site
Sofia, 1606
Research Site
Sofia, 1784
Research Site
Varna, 9010

Other trials in Bulgaria

Colombia12 sites

Research Site
Armenia, Quindío Department
Research Site
Barranquilla, Atlántico, 08001000
Research Site
Barranquilla, Atlántico, 080020
Research Site
Bogota, Cundinamarca, 11001000
Research Site
Bogota, Cundinamarca, 110221
Research Site
Bogota, Cundinamarca
Research Site
Cali, Valle del Cauca Department, 760032
Research Site
Cartagena, Departamento de Bolívar, 130010
Research Site
Floridablanca, Santander Department
Research Site
Manizales, Caldas Department
Research Site
Medellín, Antioquia, 050012
Research Site
Medellín, Antioquia, 050021

Other trials in Colombia

Spain12 sites

Research Site
Almería, Andalusia, 04120
Research Site
Córdoba, Andalusia, 14004
Research Site
El Palmar, Murcia, 30120
Research Site
Galdakao, Basque Country, 48960
Research Site
L'Hospitalet de Llobregat, Catalonia, 08907
Research Site
Madrid, 28007
Research Site
Madrid, 28034
Research Site
Sant Joan d'Alacant, Valencia, 03550
Research Site
Santiago de Compostela, Galicia, 15706
Research Site
Valencia, Valencia, 46010
Research Site
Vigo, Galicia, 36312
Research Site
Zaragoza, Aragon, 50009

Other trials in Spain

Finland11 sites

Research Site
Hämeenlinna, 13100
Research Site
Helsinki, 00180
Research Site
Helsinki, 00290
Research Site
Jyväskylä, 40100
Research Site
Kokkola, 67100
Research Site
Kuopio, 70100
Research Site
Oulu, 90029
Research Site
Oulu, 90100
Research Site
Tampere, 33100
Research Site
Tampere, 33521
Research Site
Turku, 20100

Other trials in Finland

Israel11 sites

Research Site
Hadera, 38100
Research Site
Haifa, 31048
Research Site
Haifa, 34362
Research Site
Herzliya-on-sea, 46851
Research Site
Holon, 58100
Research Site
Jerusalem, 91031
Research Site
Nahariya, 22100
Research Site
Netanya, 42470
Research Site
Rehovot, 76100
Research Site
Tel Aviv, 64239
Research Site
Tel HaShomer, 52621

Other trials in Israel

Austria10 sites

Research Site
Graz, 8036
Research Site
Innsbruck, 6020
Research Site
Linz, 4010
Research Site
Salzburg, 5020
Research Site
Vienna, 1060
Research Site
Vienna, 1090
Research Site
Vienna, 1130
Research Site
Vienna, 1160
Research Site
Vienna, 1190
Research Site
Wels, 4600

Other trials in Austria

Philippines10 sites

Research Site
Angeles, 2009
Research Site
Baguio City, 2600
Research Site
Dasmariñas Cavite, 4114
Research Site
Davao City, Davao Region, 8000
Research Site
Iloilo City, 5000
Research Site
Makati City, 1218
Research Site
Manila, 1113
Research Site
Marikiina, 1800
Research Site
Quezon City, 1100
Research Site
Quezon City, 1102

Other trials in Philippines

Portugal10 sites

Research Site
Almada, 2801-951
Research Site
Amadora, 2720-276
Research Site
Carnaxide, 2790-134
Research Site
Coimbra, 3000-075
Research Site
Covilha, 6200-251
Research Site
Lisbon, 1169-024
Research Site
Lisbon, 1350-070
Research Site
Lisbon, 1449-005
Research Site
Porto, 4100-180
Research Site
Setúbal, 2910-446

Other trials in Portugal

Taiwan10 sites

Research Site
Changhua, 50006
Research Site
Kaohsiung City, 807
Research Site
Kaohsiung City, 83301
Research Site
New Taipei City, Taipei, 251
Research Site
Taichung, 402
Research Site
Tainan, 710
Research Site
Taipei, 100
Research Site
Taipei, 10630
Research Site
Taipei, 11217
Research Site
Taoyuan, 33305

Other trials in Taiwan

Turkey (Türkiye)10 sites

Research Site
Adana, 01330
Research Site
Ankara, 06100
Research Site
Ankara, 06490
Research Site
Istanbul, 34096
Research Site
Istanbul, 34865
Research Site
Izmir, 35000
Research Site
Izmir, 35100
Research Site
Kocaeli, 41380
Research Site
Konya, 42080
Research Site
Sivas, 58140

Other trials in Turkey (Türkiye)

Latvia9 sites

Research Site
Daugavpils, 5417
Research Site
Daugavpils, LV-5410
Research Site
Kuldīga, LV-3301
Research Site
Liepāja, LV-3414
Research Site
Ogre, 5001
Research Site
Ogre, LV-5003
Research Site
Riga, 1002
Research Site
Riga, 1012
Research Site
Riga, LV-1001

Other trials in Latvia

Malaysia9 sites

Research Site
George Town, 10050
Research Site
George Town, 10400
Research Site
Johor Bahru, Johor, 80100
Research Site
Kota Kinabalu, Sabah, 88300
Research Site
Kuala Lumpur, Kuala Lumpur, 50400
Research Site
Kuala Lumpur, Kuala Lumpur, 56000
Research Site
Kuala Lumpur, 59100
Research Site
Malacca, 75400
Research Site
Taiping, Perak, 34000

Other trials in Malaysia

Norway9 sites

Research Site
Ålesund, 6003
Research Site
Bekkestua, 1357
Research Site
Bodø, 8092
Research Site
Hamar, 2317
Research Site
Lierskogen, 3420
Research Site
Oslo, 0450
Research Site
Skedsmokorset, 2020
Research Site
Skien, 3710
Research Site
Stavanger, 4005

Other trials in Norway

Switzerland9 sites

Research Site
Baden, 5404
Research Site
Basel, 4031
Research Site
Bern, 3010
Research Site
Geneva, 1211
Research Site
Lausanne, 1011
Research Site
Lugano, 6900
Research Site
Sion, 1950
Research Site
Winterthur, 8401
Research Site
Zurich, 8063

Other trials in Switzerland

Chile7 sites

Research Site
Osorno, 5311092
Research Site
Santiago, 7500520
Research Site
Santiago, 7650018
Research Site
Santiago, 8350595
Research Site
Santiago
Research Site
Temuco, Cautín, 4781156
Research Site
Temuco, Cautín, 4813299

Other trials in Chile

Estonia5 sites

Research Site
Harjumaa, 74001
Research Site
Paide, 72713
Research Site
Tallinn, 10128
Research Site
Tallinn, 10138
Research Site
Tallinn, 13419

Other trials in Estonia

Lithuania5 sites

Research Site
Kaunas, 48259
Research Site
Kaunas, 50009
Research Site
Klaipėda, 94231
Research Site
Vilnius, 08661
Research Site
Vilnius, 10323

Other trials in Lithuania

Ireland4 sites

Research Site
Ballinasloe
Research Site
Dublin, 8
Research Site
Dublin, 9
Research Site
Galway

Other trials in Ireland

New Zealand3 sites

Research Site
Christchurch, 8011
Research Site
Papatoetoe, Auckland, 2025
Research Site
Tauranga, 3143

Other trials in New Zealand

Singapore3 sites

Research Site
Singapore, 169609
Research Site
Singapore, 529889
Research Site
Singapore, 768828

Other trials in Singapore

Hong Kong2 sites

Research Site
Hong Kong
Research Site
New Territories

Other trials in Hong Kong

Iceland2 sites

Research Site
Kopavogur, 201
Research Site
Reykjavik, 101

Other trials in Iceland

About this study

Official title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Conditions: Dyslipidemia
Being tested: Evolocumab, Placebo
Keywords: High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
Medical subject headings: Dyslipidemias, Hypercholesterolemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

EvolocumabBiological
Also called AMG 145, Repatha
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
PlaceboDrug
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Study groups in NCT01764633
Study group	Role	What they receive
Placebo	Placebo comparator	Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Receives: Drug: Placebo
Evolocumab	Experimental	Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Receives: Biological: Evolocumab

What is being measured

The primary outcome is the main question the study is designed to answer.

Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization
All deaths and potential endpoint events were adjudicated by an independent external Clinical Events Committee (CEC) led by the Thrombolysis in Myocardial Infarction (TIMI) Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction".
Time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

Secondary outcomes (8)

Time to Cardiovascular Death, Myocardial Infarction, or Stroke
All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". Time to cardiovascular death, myocardial infarction, or stroke was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to Cardiovascular Death
All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction".
Cardiovascular death includes death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure (HF), death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes.
Time to cardiovascular death was defined as the time from randomization to the date of cardiovascular death and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on the last confirmed survival status date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to All Cause Death
Time to all-cause death was defined as the time from randomization to the date of death and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on the last confirmed survival status date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Myocardial Infarction
All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction".
The diagnosis of myocardial infarction required the combination of:
- Evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and
- Supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery Imaging.
Time to first myocardial infarction was defined as the time from randomization to the date of the first MI and was analyzed using Kaplan-Meier survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Stroke
All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction".
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.
Time to first stroke was defined as the time from randomization to the date of the stroke and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Coronary Revascularization
All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction".
Time to first coronary revascularization was defined as the time from randomization to the date of the coronary revascularization and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure
All events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions.
HF hospitalization was defined as an event that met all of the following criteria:
1. Admitted to hospital with a primary diagnosis of HF
2. In hospital for at least 24 hours
3. Documented new or worsening symptoms due to HF, including at least 1 of the following:
- Dyspnea
- Decreased exercise tolerance
- Fatigue
- Other symptoms of worsened end-organ perfusion or volume overload
1. Evidence of new or worsening HF consisting of at least 2 physical exam findings or 1 physical exam finding and at least 1 laboratory criterion
2. Received new or increased treatment for HF. Time to CV death or first hospitalization for worsening HF was defined as the time from randomization to the first occurrence of any component of the endpoint analyzed using KM survival analysis. Participants with no event were censored based on last non-fatal potential endpoint collection date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Ischemic Fatal or Non-Fatal Stroke or Transient Ischemic Attack
All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions.
Ischemic stroke was defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Transient ischemic attack (TIA) was defined as a transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia, without acute infarction.
Time to first ischemic fatal or non-fatal stroke or TIA was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using KM analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.
Measured: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

8 Feb 201311 Nov 2016

First posted9 Jan 2013 (estimated)
Study start8 Feb 2013
Primary completion11 Nov 2016
Study completion11 Nov 2016

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (31)Papers the sponsor has linked to this study.
Other trials for DyslipidemiaStudies of the same condition, open and under way.
More trials run by AmgenThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 27,564 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT01764633
Sponsor's protocol ID: 20110118
Other IDs: 2014/01/004324, 2012-001398-97
Acronym: FOURIER
Status last verified: May 2024
First submitted: 8 Jan 2013
Last updated: 28 May 2024
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes

Publications

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
PubMed 28304224
Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 Oct 1;2(10):1069-1078. doi: 10.1001/jamacardio.2017.2762.
PubMed 28832867
Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019 Jul 1;4(7):691-695. doi: 10.1001/jamacardio.2019.1647.
PubMed 31166576
Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug;16(4):538-543. doi: 10.1016/j.jacl.2022.05.069. Epub 2022 Jun 6.
PubMed 35760720
Berg DD, Moura FA, Bellavia A, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Bohula EA, Giugliano RP, Park JG, Feinberg MW, Braunwald E, Morrow DA, Sabatine MS. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2023 Jun 27;81(25):2391-2402. doi: 10.1016/j.jacc.2023.04.031.
PubMed 37344040
Clinical Benefit of Evolocumab Treatment Among Patients With Atherosclerotic Cardiovascular Disease: Exploration Based on the Chinese Subgroup of FOURIER Study, ZHANG Lihua1 , LI Weimin2 , YAO Zhuhua3 , CHEN Jiyan4 , DONG Jun5 , LI Jing1 (Chinese Circulation Journal, 2023, 38: 704.)
Monguillon V, Kelly PJ, O'Donoghue ML, Park JG, Bohula EA, Saver JL, Atar D, Keech AC, Sever PS, Wang H, Paiva da Silva Lima G, Sabatine MS, Giugliano RP. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation. 2026 Jan 13;153(2):86-93. doi: 10.1161/CIRCULATIONAHA.125.077549. Epub 2025 Nov 3.
PubMed 41178569
Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, Honarpour N, Keech AC, Sever PS, Sabatine MS, Giugliano RP. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025 May 20;151(20):1467-1476. doi: 10.1161/CIRCULATIONAHA.124.072756. Epub 2025 Apr 21.
PubMed 40255182
Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 Apr 18;147(16):1192-1203. doi: 10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13.
PubMed 36779348
Erviti J, Wright J, Bassett K, Ben-Eltriki M, Jauca C, Saiz LC, Leache L, Gutierrez-Valencia M, Perry TL. Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data. BMJ Open. 2022 Dec 30;12(12):e060172. doi: 10.1136/bmjopen-2021-060172.
PubMed 36585131
Fagundes A Jr, Morrow DA, Oyama K, Furtado RHM, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Keech AC, Sever P, Giugliano RP, Sabatine MS, Bergmark BA. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. J Am Coll Cardiol. 2022 Aug 30;80(9):887-897. doi: 10.1016/j.jacc.2022.05.051.
PubMed 36007987
Furtado RHM, Fagundes AA Jr, Oyama K, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BA. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2022 Mar;15(3):e011382. doi: 10.1161/CIRCINTERVENTIONS.121.011382. Epub 2022 Feb 25.
PubMed 35209731
Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, Ruzza A, Keech AC, Sever PS, Sabatine MS, Bergmark BA. Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Eur Heart J. 2021 Dec 14;42(47):4821-4829. doi: 10.1093/eurheartj/ehab604.
PubMed 34537830
Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MS; FOURIER Study Group. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Circ J. 2021 Oct 25;85(11):2063-2070. doi: 10.1253/circj.CJ-20-1051. Epub 2021 May 15.
PubMed 33980763
Oyama K, Furtado RHM, Fagundes A Jr, Zelniker TA, Tang M, Kuder J, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BA. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021 Jan 26;77(3):259-267. doi: 10.1016/j.jacc.2020.11.011. Epub 2020 Nov 13.
PubMed 33197560

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease

All Dyslipidemia trials

Study at a glance

From the registry record, last updated by the sponsor on 28 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
ClinicalTrials.gov ID: NCT01764633
Acronym / sponsor ID: FOURIER / 20110118
Conditions: Dyslipidemia
Keywords: High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 27,564 participants (actual)
Lead sponsor: AmgenIndustry (pharma, biotech, devices)
Study start: 8 Feb 2013 (actual)
Primary completion: 11 Nov 2016 (actual)
Study completion: 11 Nov 2016 (actual)
First posted: 9 Jan 2013 (estimated)
Results: Posted 15 Feb 2018

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2

Arm	Type	Receives
Placebo	Placebo comparator	Drug: PlaceboParticipants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
Evolocumab	Experimental	Biological: EvolocumabParticipants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.

Who may qualify

Ages: 40 to 85 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Male or female ≥ 40 to ≤ 85 years of age
History of clinically evident cardiovascular disease at high risk for a recurrent event
Fasting low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (> 2.6 mmol/L)
Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Key exclusion criteria (6 listed)

New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction < 30%
Uncontrolled hypertension
Uncontrolled or recurrent ventricular tachycardia
Untreated hyperthyroidism or hypothyroidism
Homozygous familial hypercholesterolemia

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
EvolocumabAlso: AMG 145, RepathaAdministered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.	Biological	Evolocumab
PlaceboAdministered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.	Drug	Placebo

Primary outcome

Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
All deaths and potential endpoint events were adjudicated by an independent external Clinical Events Committee (CEC) led by the Thrombolysis in Myocardial Infarction (TIMI) Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". Time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.

8 secondary outcomes

Time to Cardiovascular Death, Myocardial Infarction, or Stroke
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to Cardiovascular Death
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to All Cause Death
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Myocardial Infarction
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Stroke
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Coronary Revascularization
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Time to First Ischemic Fatal or Non-Fatal Stroke or Transient Ischemic Attack
Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

Results and safety

Results posted to the registry on 15 Feb 2018, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Placebo	13,780	13,662
Evolocumab	13,784	13,691

Primary outcome: Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization

Time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.. Number (95% Confidence Interval). Unit: percentage of participants

Measure	Placebo n = 13780	Evolocumab n = 13784
KM estimate at 6 months	3.11 (2.82 to 3.40)	2.74 (2.47 to 3.01)
KM estimate at 12 months	6.01 (5.61 to 6.41)	5.31 (4.93 to 5.68)
KM estimate at 18 months	8.32 (7.86 to 8.78)	7.25 (6.81 to 7.68)
KM estimate at 24 months	10.66 (10.12 to 11.19)	9.13 (8.63 to 9.63)
KM estimate at 30 months	12.72 (12.08 to 13.35)	10.91 (10.31 to 11.50)
KM estimate at 36 months	14.64 (13.76 to 15.50)	12.57 (11.70 to 13.42)

Placebo vs Evolocumab: Hazard Ratio (HR): 0.85 (95% CI 0.79 to 0.92), p < 0.0001, Log Rank

Population analysed: All randomized participants; The number of participants entered at each time point represents the number of participants at risk.

8 secondary outcomes are reported in the full results.

Adverse events

Time frame: From the first dose of study drug to the end of study. The median duration of follow-up was 26 months.. Other adverse events reported at 5% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Placebo	3,404 of 13,756 (24.7%)	3,438 of 13,756 (25%)	Not reported
Evolocumab	3,410 of 13,769 (24.8%)	3,500 of 13,769 (25.4%)	Not reported

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2024.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Background: PubMed 28304224Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
Background: PubMed 28832867Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 Oct 1;2(10):1069-1078. doi: 10.1001/jamacardio.2017.2762.
Background: PubMed 31166576Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019 Jul 1;4(7):691-695. doi: 10.1001/jamacardio.2019.1647.
Background: PubMed 35760720Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug;16(4):538-543. doi: 10.1016/j.jacl.2022.05.069. Epub 2022 Jun 6.
Background: PubMed 37344040Berg DD, Moura FA, Bellavia A, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Bohula EA, Giugliano RP, Park JG, Feinberg MW, Braunwald E, Morrow DA, Sabatine MS. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2023 Jun 27;81(25):2391-2402. doi: 10.1016/j.jacc.2023.04.031.
BackgroundClinical Benefit of Evolocumab Treatment Among Patients With Atherosclerotic Cardiovascular Disease: Exploration Based on the Chinese Subgroup of FOURIER Study, ZHANG Lihua1 , LI Weimin2 , YAO Zhuhua3 , CHEN Jiyan4 , DONG Jun5 , LI Jing1 (Chinese Circulation Journal, 2023, 38: 704.)
Derived from this study: PubMed 41178569Monguillon V, Kelly PJ, O'Donoghue ML, Park JG, Bohula EA, Saver JL, Atar D, Keech AC, Sever PS, Wang H, Paiva da Silva Lima G, Sabatine MS, Giugliano RP. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation. 2026 Jan 13;153(2):86-93. doi: 10.1161/CIRCULATIONAHA.125.077549. Epub 2025 Nov 3.
Derived from this study: PubMed 40255182Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, Honarpour N, Keech AC, Sever PS, Sabatine MS, Giugliano RP. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025 May 20;151(20):1467-1476. doi: 10.1161/CIRCULATIONAHA.124.072756. Epub 2025 Apr 21.
Derived from this study: PubMed 36779348Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 Apr 18;147(16):1192-1203. doi: 10.1161/CIRCULATIONAHA.122.063399. Epub 2023 Feb 13.
Derived from this study: PubMed 36585131Erviti J, Wright J, Bassett K, Ben-Eltriki M, Jauca C, Saiz LC, Leache L, Gutierrez-Valencia M, Perry TL. Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data. BMJ Open. 2022 Dec 30;12(12):e060172. doi: 10.1136/bmjopen-2021-060172.
Derived from this study: PubMed 36007987Fagundes A Jr, Morrow DA, Oyama K, Furtado RHM, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Keech AC, Sever P, Giugliano RP, Sabatine MS, Bergmark BA. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. J Am Coll Cardiol. 2022 Aug 30;80(9):887-897. doi: 10.1016/j.jacc.2022.05.051.
Derived from this study: PubMed 35209731Furtado RHM, Fagundes AA Jr, Oyama K, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BA. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2022 Mar;15(3):e011382. doi: 10.1161/CIRCINTERVENTIONS.121.011382. Epub 2022 Feb 25.
AmgenTrials clinical trials websiteLink provided by the sponsor.

Related trials for Dyslipidemia

Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

MD study director

Amgen

1,284 sites in 49 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Evolocumab in people with Dyslipidemia, run by Amgen at 1,284 sites in 49 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1,284 sites in United States, United Kingdom, Japan, Poland, Czechia and 44 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Feb 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization (time frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01764633, which also lists 31 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2024.